Frankfurt
30.10.26 | 08:07
5,020 Euro
+2,03 % +0,100
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,880 | 5,080 | 30.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.10. | XFRA NEW INSTRUMENTS AVAILABLE ON 20.10.2026 | 314 | Xetra Newsboard | The following instruments on XETRA do have their first trading 20.10.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.10.2026
Aktien
1 CA01451H1047 Alex Metals Corp.
2... ► Artikel lesen | |
| 02.10. | Needham raises Shattuck Labs stock price target on HS trial plans | 2 | Investing.com | ||
| 01.10. | Shattuck Labs plans phase 2 trial for SL-325 in hidradenitis suppurativa | 1 | Investing.com | ||
| 01.10. | Shattuck Labs, Inc.: Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development | 505 | GlobeNewswire (Europe) | - RECEPTIVE-HS1 Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS) expected to initiate in 2026; data from the 16-week treatment period expected in the first... ► Artikel lesen | |
| 08.09. | Shattuck Labs auf Wells Fargo Konferenz: Strategie fokussiert sich auf DR3-Blockade | 2 | Investing.com Deutsch | ||
| 25.08. | What Shattuck Labs Stock Topped the Market on Monday | 4 | The Motley Fool | ||
| 12.08. | H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion | 1 | Investing.com | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 12.08. | H.C. Wainwright senkt Kursziel für Shattuck Labs wegen Studienerweiterung | 3 | Investing.com Deutsch | ||
| 11.08. | Shattuck Labs, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 11.08. | Shattuck Labs Aktie gibt nach Quartalsbericht nach | 6 | Investing.com Deutsch | ||
| 11.08. | Shattuck Labs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.08. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Shattuck Labs GAAP EPS of -$0.12 in-line | 3 | Seeking Alpha | ||
| 11.08. | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | 592 | GlobeNewswire (Europe) | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| 25.07. | Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday | 1 | The Motley Fool | ||
| 24.07. | This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday | 1 | Benzinga.com | ||
| 24.07. | JPMorgan reiterates Shattuck Labs stock rating on DR3 program | 4 | Investing.com | ||
| 11.06. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Shattuck Labs drops 6%, prices $75M share raise at $4 per share | 1 | Seeking Alpha | ||
| 10.06. | Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr | 360 | AFX News | WASHINGTON (dpa-AFX) - Shattuck Labs, Inc. (STTK), a clinical-stage biotechnology company, on Wednesday revealed the pricing of its earlier announced public offering of 10.88 million shares... ► Artikel lesen |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,460 | +0,41 % | Valneva verliert UK-Zulassung: Warum die Aktie dennoch nicht kippt | ||
| PALATIN TECHNOLOGIES | 4,990 | -0,20 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,630 | -3,08 % | Ocugen nach MENA-Lizenz: Diese Marke entscheidet jetzt | ||
| VIVORYON THERAPEUTICS | 0,800 | -0,99 % | Vivoryon Therapeutics N.V. to Report Q3 2026 Financial Results on November 5, 2026 | Vivoryon Therapeutics N.V. to Report Q3 2026 Financial Results on November 5, 2026
Halle (Saale) / Munich, Germany, October 30, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,317 | +3,26 % | 1,9 Milliarden US-Dollar für verletzte Nerven: Warum Axogen, Integra und NurExone drei Reparaturprinzipien verfolgen | ||
| SAREPTA THERAPEUTICS | 16,700 | -0,83 % | Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth? | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,205 | -4,83 % | Here's Why You Should Hold PacBio Stock in Your Portfolio for Now | ||
| REDHILL BIOPHARMA | 0,385 | -0,70 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,158 | +6,62 % | Onco-Innovations Limited: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,200 | -0,80 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| VERASTEM | 8,710 | +1,70 % | Novocure and Verastem to Test Combined Therapies for Locally Advanced Pancreatic Cancer | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,716 | -0,51 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,150 | -1,83 % | Rocket Pharma upgraded at Goldman Sachs on Danon disease therapy | ||
| VOYAGER THERAPEUTICS | 1,633 | +5,70 % | Voyager Therapeutics, Inc.: Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026 | ||
| PALISADE BIO | 1,180 | +1,72 % | Wegner warnt Schüler vor Unterwanderung durch Pro-Pali-Initiativen | Berlin - Der noch amtierende Regierende Bürgermeister von Berlin, Kai Wegner (CDU), hat Schüler vor einer Unterwanderung ihrer Demonstrationen durch pro-palästinensische Aktivisten gewarnt. "Wir hatten... ► Artikel lesen |
SHATTUCK LABS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 5,020 Euro und damit +2,03 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.